1

2
Wallach David, Engelmann Hartmut, Aderka Dan, Rubinstein Menachem: (tnf)Inhibitory protein and its purification.. Yeda Res & Dev, March 22, 1989: EP0308378-A2 (128 worldwide citation)

Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein, salts, functional derivatives and active fractions thereof and mixtures of any o ...


3
Wallach David: A monoclonal antibody recognizing a cytotoxin, a hybridoma cell line expressing same and a process for the preparation of a purified cytotoxin.. Yeda Res & Dev, July 9, 1986: EP0186833-A2 (121 worldwide citation)

A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal anti-cytotoxin antibodies. Hybridomas secreting anti-cytotoxin antibodies are identified by a solid phase bi ...


4
Yayon Avner, Nevo Zvi: Fgfr3 as a marker for mesenchymal skeletal progenitor cells. Yeda Res & Dev, Univ Ramot, April 8, 1998: EP0833620-A1 (111 worldwide citation)

The present invention concerns fibroblast growth factor 9 (FGF9) as a high affinity ligand for fibroblast growth factor receptor 3 (FGFR3) which ligand is capable of binding and activating FGFR3 in a specific manner. The present invention is also directed to methods for detection of FGFR3 by utilizi ...


5
Wallach David, Brakebusch Cord: Multimers of the soluble forms of tnf receptors, their preparation and pharmaceutical compositions containing them.. Yeda Res & Dev, February 10, 1993: EP0526905-A2 (108 worldwide citation)

Multimers of the soluble forms of the tumor necrosis factor receptors (TNF-Rs) are provided. These multimers are produced either by chemical or by recombinant methods. The multimers of the soluble forms of TNF-Rs are useful for protecting mammals (including humans) from the deleterious effects of TN ...


6
Wallach David, Engelmann Hartmut, Aderka Dan, Novick Daniela, Rubinstein Menachem: Tumor necrosis factor binding protein ii, its purification and antibodies thereto.. Yeda Res & Dev, November 22, 1990: EP0398327-A1 (106 worldwide citation)

Tumor Necrosis Factor (TNF) Binding Protein is isolated and substantially purified. It has the ability to inhibit the cytotoxic effect of TNF and/or to maintain its prolonged beneficial effects. TNF Binding Protein II and salts, functional derivatives, precursors and active fractions thereof can be ...


7
Wallach David, Nophar Yaron, Kemper Oliver, Engelmann Hartmut, Brakebusch Cord, Aderka Dan: Expression of the recombinant tumor necrosis factor binding protein i (tbp-i).. Yeda Res & Dev, June 26, 1991: EP0433900-A1 (100 worldwide citation)

Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising a DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cells, whereby th ...


8
Wallach David, Engelmann Harmut, Aderka Dan: (ab) Fragments thereof.. Yeda Res & Dev, February 13, 1991: EP0412486-A1 (81 worldwide citation)

Antibodies to TNF Binding Protein I (TBP-I) and F(ab) fragments thereof are provided that can be used in diagnostic assays and pharmaceutical agents for either inhibiting or mimicking the effects of TNF on cells.


9
Bohak Zvi, Kadouri Avinoam, Sussman Martin: A matrix for cell cultivation in vitro. Yeda Res & Dev, February 11, 1987: GB2178447-A (61 worldwide citation)

A matrix and cultivation system for anchorage dependent cells has a substantially increased available effective surface area for cell attachment provided by a fiber network or open-pore foams with suitable pore size of 10 mu to 100 mu . Attachment of the cells can be enhanced by modifying the surfac ...


10
Revel Michel, Rubinstein Menachem, Mory Yves, Chen Louise, Novick Daniela, Michalevicz Rita: Human ifn-beta2/il-6, its purification and uses.. Yeda Res & Dev, August 2, 1989: EP0326120-A2 (56 worldwide citation)

Monoclonal antibodies to IFN- beta 2/IL-6 and hybridomas producing them and production and purification of glycosylated and unglycosylated IFN- beta 2/ IL-6 are disclosed. The protein is useful in the treatment of breast cancer, leukemia, infectious diseases and bone marrow progenitor cell disorders ...